SCHEMBL5142369

SCHEMBL5142369

O=C(Nc1cccc(C(F)(F)F)c1)C(=Cc1ccc(Cl)c(Cl)c1)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ERBB2 P04626 1/20 0.54
KDR P35968 1/20 0.51
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
LMNA P02545 2/20 0.49
PKM P14618 2/20 0.49
HSP90AA1 P07900 1/20 0.49
RAB9A P51151 2/20 0.49
HTT P42858 2/20 0.49
RXFP1 Q9HBX9 1/20 0.47
TP53 P04637 1/20 0.47
SLC2A1 P11166 1/20 0.46
P2RX1 P51575 1/20 0.46
P2RX4 Q99571 1/20 0.46
P2RX7 Q99572 1/20 0.46
TMPRSS4 Q9NRS4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142680 0.88 MAPT (0.54) MAPTALDH1A1NPSR1ERBB2KDR
SCHEMBL5142706 0.86 MAPT (0.56) MAPTALDH1A1NPSR1ERBB2KDR
SCHEMBL5142735 0.85 MAPT (0.51) MAPTALDH1A1NPSR1ERBB2KDR
SCHEMBL5145757 0.84 MEN1 (0.56) MAPTALDH1A1NPSR1ERBB2KDR
SCHEMBL5142747 0.84 KDR (0.57) MAPTALDH1A1NPSR1L3MBTL1KDR
SCHEMBL5142732 0.83 MAPT (0.62) MAPTALDH1A1NPSR1ERBB2MEN1
SCHEMBL5142386 0.82 MAPT (0.54) MAPTALDH1A1NPSR1ERBB2MEN1
SCHEMBL5145891 0.82 MAPT (0.55) MAPTALDH1A1NPSR1ERBB2MEN1
SCHEMBL5141404 0.82 SMN1; SMN2 (0.50) MAPTALDH1A1NPSR1ERBB2MEN1
SCHEMBL5142353 0.82 SLC2A1 (0.54) MAPTALDH1A1NPSR1L3MBTL1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US claimed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO claimed
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 MAPT 4733/4885ALDH1A1 952/4885NPSR1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.